Panzyga (Human Normal Immunoglobulin)

Panzyga is an immunoglobulin used to replace missing antibodies in primary immunodeficiency disorders and related immune‑deficiency conditions.

• Primary immunodeficiency disease (PID): restores normal levels of IgG and reduces infection frequency.
• Secondary immunodeficiency (e.g., chronic lymphocytic leukemia): provides passive immunity to help prevent bacterial infections.
• Post‑transplant immune support: supplies antibodies to patients whose own immune system is suppressed after organ transplantation.
• Antibody deficiency secondary to chemotherapy: supports immune function during cancer treatment.
• Primary antibody deficiency (CVID): maintains protective IgG concentrations and reduces need for antibiotics.

• Panzyga contains purified human IgG antibodies that bind a broad spectrum of pathogens, neutralising viruses, bacteria and toxins. The administered IgG is distributed through the vascular compartment, where it provides passive immunity by opsonising microbes, enhancing phagocytosis and modulating complement activation, thereby compensating for the patient’s deficient antibody production.

Adverse reactions to Panzyga are generally related to the infusion process and the immunoglobulin content.

Common Side Effects

• Headache
• Fatigue
• Mild fever
• Chills
• Nausea
• Injection site erythema

Serious or Rare Side Effects

• Anaphylactic reaction
• Acute renal failure
• Thromboembolic events
• Aseptic meningitis
• Hemolytic anemia
• Severe hypotension

When using Panzyga, clinicians should assess patient history and monitor for specific safety concerns.

• Renal function: evaluate baseline kidney function and adjust infusion rate in renal impairment.
• Thrombotic risk: assess history of clotting disorders before initiating therapy.
• Cardiovascular status: monitor blood pressure during infusion, especially in patients with cardiac disease.
• Allergic history: verify no prior severe reactions to immunoglobulin products.
• Concomitant immunosuppressants: watch for increased infection risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Panzyga may interact with other medicines that affect immune function or renal clearance.

Major Interactions (Avoid)

• Live vaccines: concurrent use may reduce vaccine efficacy and increase adverse events.
• Nephrotoxic drugs (e.g., aminoglycosides): combined use can worsen renal impairment.

Moderate Interactions (Monitor Closely)

• Anticoagulants: immunoglobulin can alter coagulation parameters, requiring INR monitoring.\n- Corticosteroids: may increase risk of fluid overload and hypertension.
• Diuretics: monitor electrolytes and volume status during infusion.
• ACE inhibitors: watch for additive effects on blood pressure.
• Rituximab: combined therapy may affect B‑cell recovery dynamics.